Sally Lettis

2.7k total citations
41 papers, 1.9k citations indexed

About

Sally Lettis is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Sally Lettis has authored 41 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 22 papers in Physiology and 7 papers in Molecular Biology. Recurrent topics in Sally Lettis's work include Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers), Asthma and respiratory diseases (21 papers) and Respiratory Support and Mechanisms (16 papers). Sally Lettis is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (27 papers), Asthma and respiratory diseases (21 papers) and Respiratory Support and Mechanisms (16 papers). Sally Lettis collaborates with scholars based in United Kingdom, United States and Denmark. Sally Lettis's co-authors include Neil Barnes, Ian Pavord, Peter M.A. Calverley, Paul Jones, Mark T. Dransfield, Fernando J. Martínez, Courtney Crim, Raj Kumar Sharma, Nicholas Locantore and Nicola A. Hanania and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and Diabetologia.

In The Last Decade

Sally Lettis

40 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sally Lettis United Kingdom	17	1.4k	1.2k	215	140	135	41	1.9k
Hungta Chen United States	21	1.1k 0.8×	896 0.7×	280 1.3×	27 0.2×	714 5.3×	106	2.1k
Alfredo Ardia Italy	12	536 0.4×	299 0.2×	139 0.6×	94 0.7×	22 0.2×	17	1.3k
Bernd Disse Germany	19	2.1k 1.5×	1.7k 1.4×	145 0.7×	101 0.7×	5 0.0×	37	2.3k
Scott E. Liebman United States	15	105 0.1×	170 0.1×	206 1.0×	99 0.7×	126 0.9×	31	993
Keita Hirai Japan	16	199 0.1×	218 0.2×	79 0.4×	16 0.1×	41 0.3×	50	690
Xueqing Yu China	15	337 0.2×	73 0.1×	128 0.6×	99 0.7×	19 0.1×	69	747
Linda J Kelly United Kingdom	12	98 0.1×	125 0.1×	284 1.3×	246 1.8×	57 0.4×	30	664
Dario Manfellotto Italy	20	87 0.1×	229 0.2×	383 1.8×	29 0.2×	88 0.7×	67	1.1k
Seung-Jung Kim South Korea	17	147 0.1×	65 0.1×	193 0.9×	122 0.9×	75 0.6×	41	793
Harry M. Vars United States	13	211 0.1×	321 0.3×	72 0.3×	94 0.7×	53 0.4×	26	1.1k

Countries citing papers authored by Sally Lettis

Since Specialization

Citations

This map shows the geographic impact of Sally Lettis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Lettis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Lettis more than expected).

Fields of papers citing papers by Sally Lettis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Lettis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Lettis. The network helps show where Sally Lettis may publish in the future.

Co-authorship network of co-authors of Sally Lettis

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Lettis. A scholar is included among the top collaborators of Sally Lettis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Lettis. Sally Lettis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crim, Courtney, Sally Lettis, Elisabeth H. Bel, et al.. (2022). IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology Global. 1(4). 198–208. 10 indexed citations

Hartley, Benjamin, et al.. (2022). Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatment. Pharmaceutical Statistics. 21(3). 612–624. 6 indexed citations

Han, MeiLan K., Gerard J. Criner, Mark T. Dransfield, et al.. (2021). Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Research. 7(1). 663–2020. 7 indexed citations

Han, MeiLan K., Gerard J. Criner, Mark T. Dransfield, et al.. (2020). The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 202(9). 1237–1243. 20 indexed citations

Lipson, David A., Courtney Crim, Gerard J. Criner, et al.. (2020). Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 201(12). 1508–1516. 146 indexed citations

Halpin, David, Gerard J. Criner, Mark T. Dransfield, et al.. (2020). Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. Pulmonary Therapy. 7(1). 101–118. 5 indexed citations

Hartley, Benjamin, Neil Barnes, Sally Lettis, et al.. (2020). Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respiratory Research. 21(1). 5–5. 20 indexed citations

Pascoe, Steven, Neil Barnes, Guy Brusselle, et al.. (2019). Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicine. 7(9). 745–756. 153 indexed citations

Rubin, David, Michael O’Neal, Sophie Bennett, et al.. (2018). Predictors of pneumonia on routine chest radiographs in patients with COPD: a post hoc analysis of two 1-year randomized controlled trials. International Journal of COPD. Volume 13. 189–201. 5 indexed citations

10.

Siddiqui, Salman, Ian Pavord, Neil Barnes, et al.. (2018). Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids. International Journal of COPD. Volume 13. 3669–3676. 23 indexed citations

11.

Pascoe, Steven, Neil Barnes, Guy Brusselle, et al.. (2018). Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT. OA2127–OA2127. 4 indexed citations

12.

Pavord, Ian, Sally Lettis, Antonio Anzueto, & Neil Barnes. (2016). Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. The Lancet Respiratory Medicine. 4(9). 731–741. 125 indexed citations

13.

Barnes, Neil, Raj Kumar Sharma, Sally Lettis, & Peter M.A. Calverley. (2016). Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. European Respiratory Journal. 47(5). 1374–1382. 166 indexed citations

14.

Crowe, Brenda, Christy Chuang‐Stein, Sally Lettis, & Andreas Brueckner. (2016). Reporting Adverse Drug Reactions in Product Labels. Therapeutic Innovation & Regulatory Science. 50(4). 455–463. 11 indexed citations

15.

Kreindler, James L., Michael L. Watkins, Sally Lettis, Ruth Tal‐Singer, & Nicholas Locantore. (2016). Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ Open Respiratory Research. 3(1). e000151–e000151. 32 indexed citations

16.

Hanania, Nicola A., Gregory Feldman, Jae-Jeong Shim, et al.. (2012). The Efficacy and Safety of the Novel Long-Acting β2 Agonist Vilanterol in Patients With COPD. CHEST Journal. 142(1). 119–127. 83 indexed citations

17.

Lettis, Sally, et al.. (2008). Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiology and Drug Safety. 17(5). 445–454. 2 indexed citations

18.

Young, Malcolm A., D.J.A. Eckland, R. Eastmond, & Sally Lettis. (1998). Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients. Annals of Medicine. 30(2). 206–212. 11 indexed citations

19.

Young, Malcolm A., Sally Lettis, & R. Eastmond. (1998). Concomitant administration of cholestyramine influences the absorption of troglitazone. British Journal of Clinical Pharmacology. 45(1). 37–40. 15 indexed citations

20.

Kumar, Sudhesh, A. J. M. Boulton, Henning Beck‐Nielsen, et al.. (1996). Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39(6). 701–709. 194 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact